Get the latest Science News and Discoveries

Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma - EurekAlert

<p><strong>Under the leadership of PD Dr. Niklas Kl&uuml;mper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the </strong><strong>Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-N&uuml;rnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin. The study, published yesterday in the prestigious Journal of Clinical Oncology, identifies NECTIN4<em> </em>amplification as a promising genomic biomarker for predicting treatment response to enfortumab vedotin. These findings could represent a significant advance in the improved treatment of this cancer.</strong></p>

None

Get the Android app